Wire · opportunities
US FDA approves Bayer's blood thinner to prevent repeat strokes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The US FDA has approved Bayer's new blood thinner, Sunharbo (asundexian), which prevents stroke recurrence by blocking Factor XIa, differing from existing treatments that target Factor Xa. This approval introduces a novel mechanism in stroke prevention and extends Bayer's portfolio amid declining revenues from older drugs.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You face fresh competition from a new blood thinner with a unique action in stroke prevention approved by the FDA. If your business is in stroke treatment drugs, you need to adapt quickly as Bayer sets a new standard that could shift market dynamics.
◆ Coverage
3 sources · 10 Nov 2026
◆ Related on Wire
◆ Topics